Caveolin-1 in Breast Cancer: Single Molecule Regulation of Multiple Key Signaling Pathways

  • Anwar, Sumadi Lukman (Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Wahyono, Artanto (Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Aryandono, Teguh (Department of Surgery, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Haryono, Samuel J (Mochtar Riady Comprehensive Cancer Center(MRCCC) Siloam Hospital Semanggi)
  • Published : 2015.11.04


Caveolin-1 is a 22-kD trans-membrane protein enriched in particular plasma membrane invaginations known as caveolae. Cav-1 expression is often dysregulated in human breast cancers, being commonly upregulated in cancer cells and downregulated in stromal cells. As an intracellular scaffolding protein, Cav-1, is involved in several vital biological regulations including endocytosis, transcytosis, vesicular transport, and signaling pathways. Several pathways are modulated by Cav-1 including estrogen receptor, EGFR, Her2/neu, $TGF{\beta}$, and mTOR and represent as major drivers in mammary carcinogenesis. Expression and role of Cav-1 in breast carcinogenesis is highly variable depending on the stage of tumor development as well as context of the cell. However, recent data have shown that downregulation of Cav-1 expression in stromal breast tumors is associated with frequent relapse, resistance to therapy, and poor outcome. Modification of Cav-1 expression for translational cancer therapy is particularly challenging since numerous signaling pathways might be affected. This review focuses on present understanding of Cav-1 in breast carcinogenesis and its potential role as a new biomarker for predicting therapeutic response and prognosis as well as new target for therapeutic manipulation.


Caveolin-1;breast cancer;signaling pathway;autophagy;prognosis;therapy


  1. Agelaki S, Spiliotaki M, Markomanolaki H, et al (2009). Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther, 8, 1470-7.
  2. Bhowmick NA, Neilson EG, Moses HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432, 332-7.
  3. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al 2010. The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle, 9, 1960-71.
  4. Bucci M, Gratton JP, Rudic RD, et al (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med, 6, 1362-7.
  5. Burke P, Schooler K, Wiley HS (2001). Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell, 12, 1897-1910.
  6. Cai C, Chen J (2004). Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer, 111, 522-9.
  7. Carroll JS, Meyer CA, Song J, et al (2006). Genome-wide analysis of estrogen receptor binding sites. Nat Genet, 38, 1289-97.
  8. Castello-Cros R, Bonuccelli G, Molchansky A, et al (2011). Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle, 10, 2021-34.
  9. Cirri P, Chiarugi P (2011). Cancer associated fibroblasts : the dark side of the coin. Am J Cancer Res, 1, 482-97.
  10. Clemons M, Goss P (2001). Estrogen and the risk of breast cancer. NEJM, 344, 276-285.
  11. Cohen AW, Razani B, Wang XB, et al (2003). Caveolin-1- deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol, 285, C222-5.
  12. Dong X, Mao S, Wen H (2013). Upregulation of proinflammatory genes in skin lesions may be the cause of keloid formation (Review). Biomed Rep, 1, 833-6.
  13. El-Gendi SM, Mostafa MF, El-Gendi AM, et al (2012). Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res, 18, 459-69.
  14. Elsheikh SE, Green AR, Rakha EA, et al (2008). Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer, 99, 327-34.
  15. Van den Eynden GG, Van Laere SJ, Van der Auwera I, et al (2006).Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat, 95, 219-28.
  16. Fielding PE, Chau P, Liu D, Spencer TA, Fielding CJ, (2004). Mechanism of platelet-derived growth factor-dependent caveolin-1 phosphorylation: relationship to sterol binding and the role of serine-80. Biochemistry, 43, 2578-86.
  17. Finn RS, Dering J, Ginther C (2007). Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat, 105, 319-26.
  18. Finn RS, Aleshin A, Dering J, et al (2013). Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology, 57, 1838-46.
  19. Fiucci G, Ravid D, Reich R, Liscovitch M, et al (2002). Caveolin-1 inhibits anchorage-independent growth anoikis and invasiveness in MFC-7 human breast cancer cells. Oncogene, 21, 2365-2375.
  20. Fujita Y, Maruyama S, Kogo H, Matsuo S, Fujimoto T (2004). Caveolin-1 in mesangial cells suppresses MAP kinase activation and cell proliferation induced by bFGF and PDGF. Kidney Int, 66, 1794-04.
  21. Giusiano S, Cochet C, Filhol O, et al (2011). Protein kinase $CK2{\alpha}$ subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays. Eur J Cancer, 47, 792-801.
  22. Glait C, Ravid D, Lee SW, Liscovitch M, Werner H (2006). Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells. FEBS Lett, 580, 5268-74.
  23. Goetz JG, Minguet S, Navarro-Lerida I, et al (2011). Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell, 146, 148-63.
  24. Gupta R, Toufaily C, Annabi B (2014). Caveolin and cavin family members: dual roles in cancer. Biochimie, 107, 188-202.
  25. Hayashi K, Matsuda S, Machida K, et al (2001). Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res, 61, 2361-64.
  26. Hino M, Doihara H, Kobayashi K, Aoe M, Shimizu N (2003). Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today, 33, 486-90.
  27. Jezierska-Drutel A, Rosenzweig SA, Neumann CA, et al (2013). Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res, 119, 107-25.
  28. Joglekar M, Elbazanti WO, Weitzman MD, Lehma H, van Golen KL (2015). Caveolin-1 mediates inflamatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase. J Cell Biochem, 116, 923-33.
  29. Kiss AL (2012). Caveolae and the regulation of endocytosis. Adv Exp Med Biol, 729, 14-28.
  30. Koo JS, Park S, Kim SI, Lee S, Park BW (2011). The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol, 32, 787-99.
  31. Lajoie P, Nabi IR (2010). Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol, 282, 135-63.
  32. Lavie Y, Fiucci G, Liscovitch M (2001). Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev, 49, 317-23.
  33. Lee H, Park DS, Razani B, et al (2002). Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol, 161, 1357-69.
  34. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE, (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 16, 1391-97.
  35. Ma X, Liu L, Nie W, et al (2013). Prognostic role of caveolin in breast cancer: a meta-analysis. Breast, 22, 462-9.
  36. Maldonado-Báez L, Williamson C, Donaldson JG (2013). Clathrin-independent endocytosis: A cargo-centric view. Exp Cell Res, 319, 2759-69.
  37. Martinez-Outschoorn U, Sotgia F, Lisanti MP (2014). Tumor microenvironment and metabolic synergy in breast cancers: Critical importance of mitochondrial fuels and function. Semin Oncol, 41, 195-216.
  38. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker- Menezes D, et al (2010). Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF${kappa}B$ activation in the tumor stromal microenvironment. Cell Cycle, 9, 3515-33.
  39. Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, et al (2011). Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator. Cell Cycle, 10, 1784-93.
  40. Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, et al (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9, 2423-33.
  41. Martinez-Outschoorn UE, Sotgia F, Lisanti MP, (2015). Caveolae and signalling in cancer. Nat Rev Cancer, 15, 225-37.
  42. Mercier I, Camacho J, Titchen K, et al (2012). Caveolin-1 and accelerated host aging in the breast tumor microenvironment: Chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol, 181, 278-93.
  43. Mercier I, Casimiro MC, Wang C, et al (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther, 7, 1212-25.
  44. Mercier I, Lisanti M (2012). Caveolin-1 and breast cancer: a new clinical perspective. Adv Exp Med Biol, 729, 83-94.
  45. Mercier I, Lisanti MP (2012). Caveolin-1 and breast cancer: a new clinical perspective. caveolins and caveolae: roles in signaling and disease mechanisms. Adv Exp Med Biol, 729, 83-94.
  46. Mineo C, Gill GN, Anderson RGW, (1999). Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem, 274, 30636-43.
  47. Orom UA, Lim MK, Savage JE, et al (2012). MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. Cell Cycle, 11, 1291-5.
  48. Otranto M, Sarrazy V, Bonte F, et al (2012). The role of the myofibroblast in tumor stroma remodeling. Cell Adh Mig, 6, 203-19.
  49. Park DS, Lee H, Frank PG, et al (2002). Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell, 13, 3416-30.
  50. Park JH, Han HJ (2009). Caveolin-1 plays important role in EGFinduced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol, 297, 935-44.
  51. Park JH, Lee MY, Han HJ, et al (2009). A potential role for caveolin-1 in estradiol-17beta-induced proliferation of mouse embryonic stem cells: involvement of Src, PI3K/Akt, and MAPKs pathways. Int J Biochem Cell Biol, 41, 659-65.
  52. Park SS, Kim JE, Kim YA, Kim YC, Kim SW (2005). Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology, 47, 625-30.
  53. Park WY, Park JS, Cho KA, et al (2000). Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem, 275, 20847-52.
  54. Patani N, Lambros MB, Natrajan R, et al (2012). Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat, 131, 307-10.
  55. Patani N, Martin LA, Reis-Filho JS, Dowsett M, (2012). The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat, 131, 1-15.
  56. Pavlides S, Tsirigos A, Migneco G, et al (2010). The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle, 9, 3485-505.
  57. White BP, Molloy MP, Zhao H, et al (2013). Extranuclear ERalpha is associated with regression of T47D PKCalphaoverexpressing, tamoxifen-resistant breast cancer. Mol Cancer, 12, 34.
  58. Perrone G, Altomare V, Zagami M, et al (2009). Caveolin-1 expression in human breast lobular cancer progression. Mod Pathol, 22, 71-8.
  59. Qian N, Ueno T, Kawaguchi-Sakita N, et al (2011). Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci, 102, 1590-6.
  60. Rao X, Evans J, Chae H, et al (2012). CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene, 32, 4519-28
  61. Ren M, Liu F, Zhu Y, et al (2014). Absence of caveolin-1 expression in carcinoma associated fibroblast of invasive micropapollary carcinoma of the breast predicts poor patient outcome. Virchows Arch, 465, 291-8.
  62. Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J, (2006). Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat, 99, 85-90.
  63. Sagara Y, Mimori K, Yoshinaga K, et al (2004). Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer, 91, 959-65.
  64. Savage K, Lambros MB, Robertson D, et al (2007). Caveolin 1 is overexpressed and amplified in a subset of basallike and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res, 13, 90-101.
  65. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP, (1999). Caveolin-1 potentiates estrogen receptor ${\alpha}$ (ER ${\alpha}$) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ER ${\aopha}$. J Biol Chem, 274, 33551-6.
  66. Schlegel A, Wang C, Pestell RG, Lisanti MP, (2001). Ligandindependent activation of oestrogen receptor alpha by caveolin-1. Bioch J, 359, 203-10.
  67. Sekhar SC, Kasai T, Satoh A, et al (2013). Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer, 4, 391-401.
  68. Senetta R, Stella G, Pozzi E, et al (2013). Caveolin-1 as a promoter of tumour spreading: When, how, where and why. J Cell Mol Med, 17, 325-36.
  69. Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R, (2012). Tyrosine-phosphorylated caveolin-1 (Tyr- 14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal Kinase (JNK). J Biol Chem, 287, 17682-92.
  70. Siegel R, Ma J, Zou Z, Jemal A, (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
  71. Simpkins SA, Hanby AM, Holliday DL, Speirs V, (2012). Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol, 227, 490-8.
  72. Sloan EK, Ciocca DR, Pouliot N, et al (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol, 174, 2035-43.
  73. Sloan EK, Stanley KL, Anderson RL, (2004). Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene, 23, 7893-7.
  74. Sotgia F (2012). Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. Annual Review of Pathology: Mechanisms of Disease, 7, 423-467.
  75. Sotgia F, Martinez-Outschoorn UE, Howell A, et al (2006). Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res, 66, 10647-51.
  76. Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al (2011). Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Br Cancer Res, 13, 213.
  77. Syeed N, Husain SA, Abdullah S, et al (2010). Caveolin-1 promotes mammary tumorigenesis: Mutational profile of the Kashmiri population. Asian Pac J Cancer Prev, 11, 689-96.
  78. Syeed N, Husain SA, Abdullah S, et al (2010). Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population. Asian Pac J Cancer Prev, 11, 1099-105.
  79. Tagawa A, Mezzacasa A, Hayer A, et al (2005). Assembly and trafficking of caveolar domains in the cell: Caveolae as stable, cargo-triggered, vesicular transporters. J Cell Biol, 170, 769-79.
  80. Thomas NB, Hutcheson IR, Campbell L, et al (2010). Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat, 119, 575-91.
  81. Tian F, Wu H, Li Z, et al (2009). Activated PKCalpha/ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells. Cancer Invest, 27, 802-8.
  82. Trimmer C, Sotgia F, Whitaker-Menezes D, et al (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther, 11, 383-94.
  83. Tryfonopoulos D, Walsh S, Collins DM, et al (2011). Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol, 22, 2234-40.
  84. Wang XX, Wu Z, Huang HF, et al (2013). Caveolin-1, through its ability to negatively regulate TLR4, is a crucial determinant of MAPK activation in LPS-challenged mammary epithelial cells. Asian Pac J Cancer Prev, 14, 2295-9.
  85. Wang Y, Yu J, Zhan Q (2008). BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem Biophys Res Commun, 370, 201-6.
  86. Wang Z, Wang N, Li W, et al (2014). Caveolin-1 mediates chemoresistance in breast cancer stem cells via ${\beta}$-catenin/ ABCG2 signaling pathway. Carcinogenesis, 35, 2346-56.
  87. Weigelt B, Geyer FC, Natrajan R, et al (2010). The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol, 220, 45-57.
  88. Williams TM, Medina F, Badano I, et al (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem, 279, 51630-46.
  89. Williams TM, Lee H, Cheung MW, et al (2004). Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis. Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Bioll Chem, 279, 24745-56.
  90. Williams TM, Lisanti MP, (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol, 288, 494-506.
  91. Williams TM, Lisanti MP, (2004). The caveolin proteins. Genome Biol, 5, 214.
  92. Witkiewicz AK, Dasgupta A, Sotgia F, et al (2009). An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol, 174, 2023-34.
  93. Witkiewicz AK, Kline J, Queenan M, et al (2011). Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle, 10, 1794-1809.
  94. Witkiewicz AK, Dasgupta A, Nguyen K, et al (2009). Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther, 8, 1071-9.
  95. Wu P, Qi B, Zhu H, et al (2007). Suppression of staurosporinemediated apoptosis in Hs578T breast cells through inhibition of neutral-sphingomyelinase by caveolin-1. Cancer Lett, 256, 64-72.
  96. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R, (2012). mTOR inhibitors in breast cancer: A systematic review. Gynecol Oncol, 127, 662-72.
  97. Zhang EY, Cristofanilli M, Robertson F, et al (2013). Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J Proteome Res, 12, 2805-17.
  98. Zou W, McDaneld L, Smith LM, (2003). Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. AntiCancer Res, 23, 4581-6.

Cited by

  1. Expression of KCNA5 Protein in Human Mammary Epithelial Cell Line Associated with Caveolin-1 vol.249, pp.4, 2016,
  2. p53 as a Regulator of Lipid Metabolism in Cancer vol.17, pp.12, 2016,
  3. gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells vol.32, pp.12, 2018,
  4. Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery vol.18, pp.1, 2018,